Geron Corporation Receives Milestone Payment From Exeter Life Sciences, Inc.

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced that is has received a milestone payment of $1.5 million from Exeter Life Sciences, Inc. as a result of the final Risk Assessment released by the U.S. Food and Drug Administration addressing food products made from cloned animals or their progeny. The Risk Assessment, available at http://www.fda.gov/cvm/CloneRiskAssessment_Final.htm, concluded that consumption of such food products poses no greater risk than consumption of food products from animals produced by conventional breeding methods.